TEM Quantitative Stock Analysis

Validea's guru fundamental report indicates that TEMPUS AI INC (TEM) receives a 55% rating based on Partha Mohanram's P/B Growth Investor model, which favors low book-to-market stocks with sustained growth characteristics; the model shows strengths in book/market ratio, cash flow to assets, return on assets variance, and capital expenditures to assets, but weaknesses in return on assets, sales variance, advertising to assets, and research and development to assets.

Analysis

Tempus AI (TEM) presents a mixed and weak profile based on Validea's P/B Growth Investor model, scoring just 55%, a figure significantly below the 80% threshold that indicates model interest. The analysis reveals a conflict between value and growth characteristics. On one hand, TEM passes criteria typical of a value stock, including a low book-to-market ratio, positive cash flow from operations relative to assets, and stable return on assets variance. However, it fails on several metrics critical for a growth investment. Most notably, the company exhibits a poor absolute Return on Assets (ROA), indicating inefficient use of its asset base to generate profit. Furthermore, its failure on sales variance suggests revenue growth is unstable, undermining the model's objective of identifying sustained future growth. For a firm in the Biotechnology & Drugs industry, the failure on the Research and Development to Assets metric is a significant concern, raising questions about its commitment to future innovation, a primary long-term value driver in this sector.

Key Decisions for Investors

• Given the sub-par 55% score on the growth model, which is well below the 80% interest threshold, investors should view TEM with considerable caution, recognizing the significant fundamental weaknesses identified.
• A deeper due diligence is required to understand the poor Return on Assets and high sales variance, as these factors directly challenge the investment thesis for a high-quality growth company.
• The failure on the Research and Development to Assets metric is a major red flag for a biotech and AI firm, warranting close scrutiny of its innovation pipeline and long-term competitive positioning.
• While the stock passes tests related to its low book-to-market ratio and cash flow, these value characteristics are currently overshadowed by a clear lack of demonstrated, stable growth, creating a conflicting investment profile.